nach oben

Current Treatment Options in Neurology

Erschienen in:

01.04.2018 | Headache (JR Couch, Section Editor)

Headache and Its Management in Patients With Multiple Sclerosis

verfasst von: Farhat Husain, MD, Gabriel Pardo, MD, Meheroz Rabadi, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The purpose of this review was to discuss the prevalence, impact, pathophysiology, and treatment of headaches (H/As) in patients with multiple sclerosis (MS).

Recent findings

Headaches and multiple sclerosis are more common in women than in men with the ratio of female to male being 3:1. It is not entirely clear if there is a correlation or an incidental comorbidity of two neurological conditions. A review of the literature shows a variable prevalence of H/As in MS patients. Using the International Classification of Headache Disorders (ICHD) criteria, the primary type of H/As, especially migraine, is the most common type seen in patients with MS. One of the theories of the pathophysiologic mechanisms of migraine in MS patients is inflammation leading to demyelinating lesions in the pain-producing centers in the midbrain. Secondary H/As due to MS medications such as interferons are also frequently present.

Summary

H/As can be a cause for significant comorbidity in patients with MS. The treatment of H/As in patients with MS should be addressed in the same fashion as in the non-MS population, which is a combination of pharmacological and non-pharmacological methods. Preventive medicines for the H/As should be carefully selected because of their side effect profiles. Acute attacks of migraines can be treated with medications such as triptans. Patients with MS who have migraine H/As should be educated about the phenomenon of overuse H/As, keeping headache journals, avoiding stress, and monitoring sleeping habits. The presence of depression in patients with MS and migraine affects quality of life (QOL) and should also be addressed for better outcomes.

Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States. Data from the American migraine study 11. Headache. 2001;41:646–57.CrossRefPubMed

www.msif.org/wp-contents/wp-contents/uploads/2014

Evans et al. Incidence and prevalence of multiple sclerosis in the Americas: a systemic review. Neuroepidemiology 2013; 40(3):195–210.

• Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler J. 2014;20(5):520–6. This review addresses the sex differences in susceptibility to MS and addresses the interactions of hormonal genetic and epigenetic factors.CrossRef

Lublin F. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(sup 11):1–5. https://doi.org/10.1159/000367614.CrossRefPubMed

• Mohrke J, Kropp P, Zettl. Headaches in multiple sclerosis might imply an Inflammatorial process. PLoS One. 2013;8(8):e69570. This study found a higher incidence of headaches in the relapsing remitting type of MSCrossRefPubMedPubMedCentral

International Association for the Study of Pain, 2011. https://s3.amazonaws.com/.../HeadacheFactSheets/1-Epidemiology.pdf.

Tabby D, Hassan M, Youngman B, Wilcox J. Headache in multiple sclerosis. Int J MS Care. 2013:73–80.

Lenore L, Terwindt G, Ferrari M. The prevalence and characteristics of migraine in a populationbased cohort: the GEM study. Neurology. 1999;53(3):537–42.CrossRef

10.

Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol. 2008;7:354–61.CrossRefPubMed

11.

Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine; results from American migraine prevalence and prevention study. Headache. 2012;52(1):3–17.CrossRefPubMed

12.

Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact. The HIT-6. Qual Life Res. 2003;12:963–74.CrossRefPubMed

13.

Finocchi C, Strada L. Sex -related differences in migraine. Neurol Sci. 2014;35(Suppl 1):S207–13.CrossRef

14.

La Mantia L, Prone V. Headache in multiple sclerosis and autoimmune disorders. Neurol Sci. 2015;36(Suppl 1):S75–8.CrossRef

15.

ICHD-3 beta. Cephalalgia. 2013;33(9):629–808. https://doi.org/10.1177/03331024134856.

16.

Manzoni GC, Bonavita V, Bussone G, et al. Chronic migraine classification: current knowledge and future perspectives. J Headache Pain. 2011;12:585–92.CrossRefPubMedPubMedCentral

17.

Dodick D. Chronic daily headache. NEJM. 2006;354:158–65.CrossRefPubMed

18.

Compston N, McAlpine D. Some aspects of the natural history of disseminated sclerosis. Q J Med. 1952;21:135–67.PubMed

19.

Villani V, De Giglio L, Prosperini L, Sette G, Pozzilli C, Salvetti M, et al. Determinants of severity of comorbid migraine in multiple sclerosis. Neurol Sci. 2012;33:1345–53.CrossRefPubMed

20.

• Kister I, Caminero AB, Monteith A, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic course. J Headache Pain. 2010;11:417–25. Study demonstrated higher frequency of rates of depression, anxiety and episodic neurologic dysfunction in patient with MS who also have migraines.CrossRefPubMedPubMedCentral

21.

Kister I, Caminero A, Herbert J, Lipton RB. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14:441–8.CrossRefPubMed

22.

Villani V, Prosperini L, Ciuffoli A, Pizzolato R, Salvetti M, Pozzilli C, et al. Primary headache and multiple sclerosis: preliminary results of a prospective study. Neurol Sci. 2008;29:S146–8.CrossRefPubMed

23.

Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia –diagnosis and treatment. Cephalalgia. 2016:1–10. https://doi.org/10.1177/0333102416687280.

24.

Boneschi FM, Colombo B, Annovazzi P, Martinelli V, Bernasconi L, Solaro C, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14:514–21.CrossRef

25.

Fallata A, Salter A, Tyry T, Cutter G, Marrie R. Trigeminal neuralgia commonly precedes diagnosis of multiple sclerosis. IJMSC. 2017;19:240–6.PubMedPubMedCentral

26.

Santi L, Annunziata P. Symptomatic cranial neuralgias in multiple sclerosis. Clinical features and treatment. Clin Neurol Neurosurg. 2012:101–7.

27.

Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54:1368–70.CrossRefPubMed

28.

•• Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by interferon-ß therapy in patients with multiple sclerosis. Acta Neurol Scand. 2012;125:91–5. Study shows that treatment with IFN -β can worsen pre-existing and also cause new H/As in patients with MS.CrossRefPubMed

29.

Polman C, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.CrossRefPubMed

30.

•• Magliozzi R, Howell O, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93. Discovery of B -follicles in meningeal infiltrates may be cause of irritation and serve as a trigger for primary headaches in MSCrossRefPubMed

31.

Pakpoor J, Handel A, Giovannoni G, Dobson R, Ramagopalan S. Meta-analysis of the relationship between Mutiple sclerosis and migraine. PLoS One. 2012;7(9):e45295.CrossRefPubMedPubMedCentral

32.

Merkler D, Klinker F, Jurgens T, et al. Propagation of spreading depression inversely correlates with cortical myelin content. Ann Neurol. 2009;66:355–65.CrossRefPubMed

33.

Gee J, Chang J, Dublin A, Vijayan N. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. Headache. 2005;45(6):670–7.CrossRefPubMed

34.

Marrie R, Cohen J, Stuve O, Trojano M, Sorensen P, Reingold S, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J. 2015;21(3):263–81.CrossRef

35.

Marrie R, Fisk J, Tremlett H, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85:1972–9.CrossRefPubMedPubMedCentral

36.

•• Marrie R, Reingold S, Cohen J, Stuve O, Trojano M, Soelberg S, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler J. 2015;21(3):305–17. This review establishes comorbidity of psychiatric disorders in patients with MSCrossRef

37.

Feinstein A. Multiple sclerosis and depression. Mult Scler J. 2011;17(11):1276–81.CrossRef

38.

Murphy R, O’Donoghue, Counihan T, et al. Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:697–708.CrossRefPubMed

39.

D’Amico D, Libro G, Prudenzano MP, et al. Stress and chronic headache. J Headache Pain. 2000;1:S49–52.CrossRefPubMedCentral

40.

Lampl C, Thomas H, Tassorelli C, et al. Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain. 2016;17:59.CrossRefPubMedPubMedCentral

41.

Manack A, Buse D, Lipton R. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70–8.CrossRefPubMed

42.

Marrie RA, Horwitz R, Cutter, et al. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012;125:180–6.CrossRefPubMed

43.

Elliott D. Migraine in multiple sclerosis. Int Rev Neurobiol. 79:281–301.

44.

Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon Beta 1-a for disease progression in relapsing Mutiple sclerosis. Ann Neurol. 1996;39:285–96.CrossRefPubMed

45.

Nicoletti P, Pappalaedo A, Castioglione A, et al. Frequency and severity of headache is worsened by interferon-β therapy in patients with multiple sclerosis. Acta Neurol Scand. 2012;125:91–5.PubMed

46.

Mantia L. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler. 12:476–80.

47.

Gelfand A, Gelfand J, Goadsby P. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2:73–9.CrossRefPubMed

48.

Polman C, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of Natalizumab for Rlapsing multiple sclerosis. NEJM. 2006;354:899–910.CrossRefPubMed

49.

Villani V, Prosperini L, Giglio L, Pozzilli C, Salvetti M, Sette G. The impact of interferon Beta and Natalizumab on comorbid migraine in Mutiple sclerosis. Headache. 2012;52:1130–5.CrossRefPubMed

50.

Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.CrossRefPubMed

51.

O’Connor P, Wolinsky J, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303.CrossRefPubMed

52.

Kappos L, Gold R et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled phase 11b study. www. the lancet.com. 2008;372:1463–1472.

53.

CAMMS223 Trial Investigators. Alemtuzumab vs. interferon Beta 1-a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.CrossRef

54.

Hauser S, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta- 1a in relapsing multiple sclerosis. Headache. 2014;376(3): 221–234.

55.

Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon Beta -1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–28.CrossRefPubMed

56.

•• Solomon A, Bourdette D, Cross A, et al. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology. 2016;87:1393–9. This review emphasizes the frequency of migraine being misdiagnosed as MS and recommends the correct use of McDonald criteria to avoid unnecessary exposure to MS treatments with potential side effectsCrossRefPubMedPubMedCentral

57.

Kastiari C, Vikelis M, Paraskevopoulou, Sfikakis P, Misikostas. Headache in systematic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache. 2011;51:1398–407.

58.

John S, Hajj-Ali RA. Headache in autoimmune diseases. Headache. 2014; 572–582.

59.

Mantia L, Erbetta A. Headache and inflammatory disorders of the central nervous system. Neurol Sci. 2004;25:S148–53.CrossRefPubMed

60.

Cuadrado MJ, Sanna G. Headache and systemic lupus erythematosus. Lupus. 2003;12:943–6.CrossRefPubMed

61.

Toledano M, Weinshenker B, Solomon A. A clinical approach to the differential diagnosis of multiple sclerosis. Curr Neurol Neurosci Rep. 2015;15:57. https://doi.org/10.1007/s11910-015-0576-7.CrossRefPubMed

62.

Alroughani R, Ahmed S, Khan R, Al-Hashel J. Status migrainosus as an initial presentation of multiple sclerosis. Alroughani et al. Springer Plus. 2015;4:28.

63.

Lin G-Y, Wang C-W, Chiang T, Peng G-S, Yang F-C. Multiple sclerosis presenting initially with a worsening of migraine symptoms. J Headache Pain. 2013; 14:70.

64.

Gebhardt M, Kropp P, Jurgens T, Hoffmann F. Headache in the first manifestation of Multiple Sclerosis-Prospective, multicenter study. Brain Behav. 2017: e00852. https://doi.org/10.1002/brb3.852 .

65.

Okuda D. Incidental lesions suggesting multiple sclerosis. Continuum. 2016;22(3):730–43.PubMed

66.

Applebee A. The clinical overlap of multiple sclerosis and headache. Headache. 2012;52(S2):111–6.CrossRefPubMed

67.

Polman C, Reingold S, Banwell B, et al. Diagnostic criteria for multiple sclerosis. 2010 revisions to the mc Donald criteria. Ann Neurol. 2011;69(2):292–302.CrossRefPubMedPubMedCentral

68.

Thompson A, Banwell B, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.CrossRefPubMed

69.

Lipton R, Bigal M, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive study. Neurology. 2007;68:343–9.CrossRefPubMed

70.

•• Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709–20. Article describes updated guidelines for preventive treatment in migraine and discusses mode of action of different agents.CrossRefPubMedPubMedCentral

71.

Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–61.CrossRefPubMed

72.

Silberstein S, Holland S, Freitag F, Dodick D, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45.CrossRefPubMedPubMedCentral

73.

D’Amico D, Tepper S. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4(6):1155–67.CrossRefPubMedPubMedCentral

74.

Silberstein S. Preventive migraine treatment. Continuum. 2015;21(4):973–89.PubMedPubMedCentral

75.

Schaefer S, Gottschalk C, Jabbari B. Treatment of chronic migraine with focus on botulinum neurotoxins. Toxins. 2015;7:2615–28.CrossRefPubMedPubMedCentral

76.

Barbanti P, Ferroni P. Onabotulinum toxin a in the treatment of chronic migraine: patient selection and special considerations. J Pain Res. 2017;10:2319–29.CrossRefPubMedPubMedCentral

77.

Rizzoli P. Acute and preventive treatment of migraine. Continuum. 2012;18(4):764–82.PubMed

78.

• Charles A. Migraine. N Engl J Med. 2017;377:553–61. Article discusses diagnostic criteria for migraine and discusses treatment strategies for acute attacks and preventive treatment.CrossRefPubMed

79.

Colman I, Friedman B, Brown M, Innes G, Grafstein E, Roberts T, et al. Parenteral dexamethasone for acute severe migraine headache: meta –analysis of randomized controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359–61. https://doi.org/10.1136/bmj.39566.806725.BE.CrossRefPubMedPubMedCentral

80.

Jette N, Amoozegar F, Patten S. Depression in epilepsy, migraine and multiple sclerosis. Neurol Clin Pract. 2017;7(2):118–27.CrossRefPubMedPubMedCentral

81.

Harden C, Pennell P, Koppel B, et al. Management issues for women with epilepsy. Epilepsia. 2009;50(5):1247–55.CrossRefPubMed

82.

Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34.CrossRefPubMed

85.••

Silberstein S, Dodick D, Bigal M Et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017. 377(22):2113–2132. This paper reports positive results from a phase 3 trial of the use of the monoclonal antibody targeting CGRP in chronic migraine.

84.

Kabat-Zinn J. Wherever you go, there you are: Mindfulness meditation in everyday life. Hyperion 1994. ISBN. 10: 1401307787.

85.

Andrasik F, Grazzi L, D’Amico D, Sansone E, Leonardi M, Raggi A, et al. Mindfulness and headache: a “new” old treatment, with new findings. Cephalalgia. 2016;36(12):1192–205.CrossRefPubMed

86.

Gilbertson R, Klatt M. Mindfulness in motion for people with multiple sclerosis: a feasibility study. Int J MS Care. 2017:225–31.

87.

Vickers A, Rees R, Zollman C et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomized trial. BMJ 2004. doi:https://doi.org/10.1136/bmj.38029.421863.EB.

88.

Zhao L, Chen J, LiY ETAL. The long-term effect of acupuncture for migraine prophylaxis. A randomized clinical trial. JAMA Intern Med. 2017;177(4):508–15.CrossRefPubMed

Titel: Headache and Its Management in Patients With Multiple Sclerosis
verfasst von: Farhat Husain, MD
Gabriel Pardo, MD
Meheroz Rabadi, MD
Publikationsdatum: 01.04.2018
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 4/2018
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-018-0495-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Headache and Its Management in Patients With Multiple Sclerosis

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie